Previous studies have shown the ability of BMP9 to induce vascular normalisation in Lewis lung carcinoma17 and breast cancer,50 but the method of overexpressing BMP9 in tumour cells is not suitable for clinical cancer immunotherapy, as it is often associated with serious problems such as immunogenicity and cytotoxicity.74 Here, GDF2 is linked to breast carcinoma.